Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2015, Pages 104-113

  Xu, Huiping ^a   O'Gorman, Melissa ^a   Boutros, Tanya ^a   Brega, Nicoletta ^a   Kantaridis, Constantino ^a   Tan, Weiwei ^a   Bello, Akintunde ^a  

^a PFIZER INC   (United States)

Author keywords

absolute bioavailability; bioequivalence; crizotinib; pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CRIZOTINIB; DRUG METABOLITE; PF 06260182; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; FATIGUE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; GINGIVITIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON SMALL CELL LUNG CANCER; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SINGLE DRUG DOSE; SOMNOLENCE; TOOTH ABSCESS; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VOMITING; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; DIET RESTRICTION; FOOD DRUG INTERACTION; MEDICINAL CHEMISTRY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FASTING; FOOD-DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84919715715     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.356     Document Type: Article

References (12)

1. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001; 19 (6): 1734-1742.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350 (21): 2129-2139.
3. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304 (5676): 1497-1500.
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101 (36): 13306-13311.
5. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004; 10 (4): 1212-1218.
6. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005; 11 (18): 6414-6421.
7. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131 (6): 1190-1203.
8. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448 (7153): 561-566.
9. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007; 6 (12 Pt 1): 3314-3322.
10. Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC,. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer. 2012; 48 (7): 961-973.
11. Yamazaki S, Skaptason J, Romero D, et al. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos. 2011; 39 (3): 383-393.
12. Li C, Alvey C, Bello A, Wilner KD, Tan W,. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol. 2011; 29: (suppl; abstr e13065).